



# GLAND PHARMA LIMITED

May 09, 2024

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
25<sup>th</sup> floor, Dalal Street  
Mumbai - 400 001  
Scrip Code: 543245

National Stock Exchange of India Limited  
Listing Department  
Exchange Plaza, 5th floor  
Plot no. C-1, Block G, Bandra Kurla Complex Bandra  
(East), Mumbai - 400 051  
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

**Sub: Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

This is to inform you that a meeting of the Board of Directors of Gland Pharma Limited ('the Company') will be held on **Wednesday, May 22, 2024** *inter alia*:

- to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31, 2024
- to consider and recommend the payment of Final Dividend for FY 2023-24

**Trading Window:**

In continuation to our earlier intimation dated March 26, 2024; this is to inform you that the trading window, which was closed from **Wednesday, March 27, 2024** in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended; will reopen on **Saturday, May 25, 2024**.

**Earnings Call:**

The Investor/Analyst call will be held on **Wednesday, May 22, 2024** at 18:30 Hrs (IST). Further details will be intimated to the stock exchanges and published on the Company's website ([www.glandpharma.com](http://www.glandpharma.com)) in due course.

This is for your information and records.

**Yours truly,  
For Gland Pharma Limited**

**Sampath Kumar Pallerlamudi  
Company Secretary and Compliance Officer**